# Efficacy of pulsed electromagnetic field therapy on acute radiodermatitis in breast cancer patients: a randomized controlled study

**Authors:** Mahmoud Hamada Mohamed, Mohamed N. Selim, Marwa Elsayed Mohamed, Mohamed Magdy Elmeligie, Ahmed Mahmoud Kadry, Reda Kotb Abdelrazik, Sara Mohamed Samir, Roshdy Mohamed Kamel, Kamaleldin Ahmed kamal, Mahmoud Elshazly

PMC · DOI: 10.1007/s00520-026-10322-9 · Supportive Care in Cancer · 2026-02-05

## TL;DR

This study found that pulsed electromagnetic field therapy helps breast cancer patients recover faster from radiation-induced skin reactions.

## Contribution

The study provides new evidence that PEMF therapy improves recovery from acute radiodermatitis in breast cancer patients undergoing radiotherapy.

## Key findings

- Skin thickness decreased significantly in PEMF-treated patients by week 6 compared to controls.
- PEMF patients had milder skin reactions and faster recovery compared to controls.
- At 8 weeks, 52% of PEMF patients returned to normal skin condition versus 8% in controls.

## Abstract

The objective of this research was to synthesize the evidence about the usage of pulsed electromagnetic field (PEMF) in women with breast cancer undergoing hypo-fractionated whole-breast irradiation (HFWBI) for the treatment of acute radiodermatitis.

The study included 50 patients (35–55 years) with unilateral breast cancer post-lumpectomy who received HFWBI. They were randomized into Group A (PEMF plus standard skin care) and Group B (standard skin care only). Skin reactions were assessed during PEMF therapy using sonographic skin thickness measurements and RTOG criterion.

After radiation, skin thickness increased in both groups, peaking at 4 weeks (PEMF 2.82 mm; control 2.74 mm, p = 0.030). By 6 weeks, thickness declined in the PEMF group but remained high in controls (p < 0.001), and by 8 weeks PEMF returned near baseline (2.01 mm) while controls stayed thickened (p < 0.001). Skin reactions worsened in both groups by week 4, with more severe cases in controls (36% vs. 12%, p = 0.150). By week 6, PEMF patients mostly had mild reactions (72% Grade 0–1) compared to predominantly severe reactions in controls (84% Grade 2–3, p = 0.001). At 8 weeks, recovery was greater with PEMF, as 52% returned to Grade 0 versus only 8% in controls (p = 0.001).

Results such as these indicate that PEMF therapy accelerates recovery from radiotherapy and diminishes the intensity of acute radiodermatitis.

Trial registration number: NCT06003764. Date of registration: 12 August 2023. Prospectively registered for prospectively registered trials.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PEMT (phosphatidylethanolamine N-methyltransferase) [NCBI Gene 10400] {aka PEAMT, PEMPT, PEMT2, PLMT}
- **Diseases:** toxicities (MESH:D064420), bleeding (MESH:D006470), ulceration (MESH:D014456), cancer (MESH:D009369), fibrosis (MESH:D005355), desquamation (MESH:D017490), dermatitis (MESH:D003872), infection (MESH:D007239), erythema (MESH:D004890), breast cancer (MESH:D001943), inflammation (MESH:D007249), pain (MESH:D010146), necrosis (MESH:D009336), skin (MESH:D012871), PEMF (MESH:D007922), Mortality (MESH:D003643), wounds (MESH:D014947), edema (MESH:D004487), diabetic (MESH:D003920), radiation (MESH:D011832), sweating (MESH:D013543), ARD (MESH:D011855), oedema (MESH:C536897), atopic dermatitis (MESH:D003876)
- **Chemicals:** silicone (MESH:D012828), Ca2 + (-), oxygen (MESH:D010100)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12876086/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12876086/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12876086/full.md

---
Source: https://tomesphere.com/paper/PMC12876086